GERN — GERON CORP
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 886744 ·
Last close
$1.52
Market Cap
$976.56M
52W High
$1.65
52W Low
$1.08
ADV30
9,850,904
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 57,480,000 | 48,240,000 | -12,653,000 | -16,680,000 | 519,009,000 | 62,643,000 | 300,395,000 |
| Mar 2026 | 51,837,000 | 50,145,000 | -236,000 | -3,642,000 | 534,120,000 | 68,895,000 | 305,012,000 |
| Dec 2025 | 48,015,000 | 46,709,000 | -8,508,000 | -28,862,000 | 570,540,000 | 77,560,000 | 344,668,000 |
| Sep 2025 | 47,227,000 | 46,184,000 | -13,887,000 | -18,428,000 | 567,382,000 | 78,117,000 | 318,675,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-125,964,000
Investing CF
$106,664,000
Financing CF
$4,436,000
CapEx
$-252,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.11
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,876,163,000
Inventory
$123,604,000
Receivables
$53,503,000
ST Investments
$238,206,000
EBIT TTM
$-37,378,000
Pretax Income TTM
$-67,612,000
Interest Exp TTM
$30,234,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$204,559,008
EBITDA
$-34,799,000
Free Cash Flow
$-78,371,752
Enterprise Value
$797,854,592
Total Cash
$300,848,992
Total Debt
$122,144,000
Shares Out
642,473,409
Trailing EPS
$-0.11
Book Value
$0.34
ROE
-28.3%
ROA
-4.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 183,881,000 | -51,553,000 | -83,500,000 | 570,540,000 | 344,668,000 | — | -111,037,000 |
| Dec 2024 | 76,994,000 | -173,732,000 | -174,572,000 | 593,781,000 | 313,461,000 | — | -218,618,000 |
| Dec 2023 | 237,000 | -193,944,000 | -184,127,000 | 394,076,000 | 146,127,000 | — | -167,743,000 |
| Dec 2022 | 596,000 | -138,550,000 | -141,901,000 | 190,575,000 | 110,577,000 | — | -127,379,000 |
TTM Snapshot
Revenues TTM
$28,271,000
NetIncome TTM
$-26,447,000
OpCashFlow TTM
$0
Assets (Latest)
$593,781,000
Forward EPS
$0.04
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PCRX | Pacira BioSciences, Inc. | $978.19M | $24.86 | — |
| IMMX | Immix Biopharma, Inc. | $968.90M | $13.61 | — |
| ARDX | ARDELYX, INC. | $965.62M | $3.74 | — |
| ANNX | Annexon, Inc. | $959.27M | $5.06 | — |
| DSGN | Design Therapeutics, Inc. | $953.12M | $15.23 | — |
News headlines (Yahoo Finance, 1h cache)
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-18 20:01 · Yahoo
Geron (GERN) Back In Focus As Fresh Guidance And Earnings Test Its Undervalued Narrative
2026-08-09 08:11 · Yahoo
Geron (GERN) Q2 2026 Earnings Call Transcript
2026-08-06 04:28 · Yahoo
Geron Corp (GERN) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ...
2026-08-05 19:04 · Yahoo
Geron (GERN) Reports Q2 Loss, Beats Revenue Estimates
2026-08-05 13:00 · Yahoo
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-07-14 20:26 · Yahoo
Geron (GERN) Grants Inducement Stock Options to New Employees
2026-07-14 10:34 · Yahoo
Geron Announces Appointment of Chinmaya Rath as Chief Business Officer
2026-07-13 12:00 · Yahoo
After Plunging 26.6% in 4 Weeks, Here's Why the Trend Might Reverse for Geron (GERN)
2026-06-04 13:35 · Yahoo
Geron (GERN) Stock Looks Reasonable On Sales But Weak On Returns
2026-08-10 07:09 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.